Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering takes Primovist MRI (magnetic resonance imaging) liver agent to Sweden:

This article was originally published in Clinica

Executive Summary

Schering has moved a step closer to selling its MRI-based liver contrast agent throughout Europe, after gaining market approval for the product in Sweden. Primovist is a gadolinium-based contrast medium that is specifically taken up by liver cells. It is designed to simultaneously detect, locate and distinguish various types of liver lesions, including liver tumours, metastases and other malignant and benign lesions. Based on the Swedish registration, the Berlin, Germany company said it would start a mutual recognition procedure for the EU, with Sweden acting as reference member state. EU registration is expected in most countries within 2004, the firm predicted. Submissions for approval in Japan and other Asian countries, where liver examinations are particularly frequent, are also planned to take place this year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel